Moderna

Today we announced that we have submitted an application to the U.S. Food and Drug Administration for review of our Spikevax 2025-2026 formula, a COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1. Read more: https://lnkd.in/esTqSGJn.

Today we announced an update on our BLA submission for our combination vaccine against influenza and COVID-19. Read more: https://lnkd.in/eWYmEZ6z

Today, on #ClinicalTrialsDay, we pause to thank the people who make progress in medicine possible.    To the participants who lend their time, trust and courage.  To the researchers who push the boundaries of science.  To the coordinators, nurses and support staff who keep it all running.    Your contributions help turn scientific discovery into real-world impact for patients.    Thank you for everything you do.

START has officially dosed the first U.S. participant in Moderna’s Phase 1 clinical trial of mRNA-4106, a novel pan-tumor antigen therapy candidate for advanced solid tumors. https://lnkd.in/eN_w8Y6F This first-in-human study represents more than just a scientific milestone—it’s a demonstration of what’s possible when innovation meets access. The trial was initiated at START San Antonio, led by Dr. Amita Patnaik, MD, FRCPC, who shared, “mRNA represents a bold new frontier in cancer immunotherapy, and we’re proud to provide our patients access to this innovative treatment as part of a first-in-human trial.” Our CEO, Nick Slack, MBE, emphasized the impact of this moment: “This milestone reflects the core of who we are at START—accelerating the next generation of cancer therapies by bringing them directly to patients in the communities where they live.” We’re proud to partner with Moderna and contribute to advancing mRNA-based innovation in oncology. Learn more about the study: https://lnkd.in/eQE7-WJG #oncologyresearch #mRNA #clinicaltrials #oncology

Skin cancer is the most common cancer in the U.S.—but it's also one of the most preventable. Most skin cancers, including melanoma—the deadliest form—are caused by UV exposure from the sun, tanning beds or sunlamps.    This Melanoma and Skin Cancer Awareness Month, here are 3 things to remember to help protect yourself and your loved ones:    ☀️ Know your risk – Anyone can get skin cancer, but certain factors raise the risk.  🧴 Reduce your exposure – Think sunscreen, shade and protective clothing.  🕵️♀️ Monitor your skin – Melanoma is easier to treat the earlier it’s diagnosed.    Prevention is powerful. This summer, protect your skin and share the facts.    Learn more: https://lnkd.in/e5_z7APx

Earlier today, we reported financial results and provided business updates for the first quarter of 2025.    For the latest episode of our #IRInsights series, members of our executive team sat down to provide more insight into our financial performance and upcoming late-stage pipeline milestones.    Watch the full video here: https://lnkd.in/ePBpt7QG

Today, we reported financial results and provided business updates for the first quarter of 2025.   Read more: https://lnkd.in/eqvEYTWw

At Moderna, we recognize that human and planetary health are interconnected—and that we have a responsibility to grow in a way that protects the planet and minimizes our environmental impact.    To celebrate Earth Day, colleagues from our Cambridge, Massachusetts, office rolled up their sleeves to clean and care for the tree wells in the neighborhood surrounding our headquarters, contributing to a healthier environment in the community we call home.    This is just one way we’re putting our values into action. We recently achieved validation of our near-term and net-zero science-based targets by the Science Based Targets initiative (SBTi)—a major milestone in our journey to reach net-zero greenhouse gas emissions across our value chain by 2045.    Learn more about how we’re building a more sustainable future: https://lnkd.in/eR-A3EsK

We’re excited to announce that the Moderna Innovation and Technology Centre (MITC), located in Harwell, Oxfordshire, has been granted a Manufacturer’s/Importer’s Authorization (MIA) by the Medicines and Healthcare products Regulatory Agency (MHRA).   This follows a successful inspection confirming the facility’s compliance with the principles and guidelines of Good Manufacturing Practice (GMP), which enables the MITC to become fully operational and on track towards producing mRNA vaccines in the UK in 2025. With the manufacturer’s license now in place, we can move forward with commercial mRNA vaccine manufacture, which will be subject to the standard regulatory review processes with the MHRA.   Just two years since breaking ground at the site, we’re proud to look ahead to delivering British-made vaccines to the UK public—supporting the NHS, enhancing the country’s pandemic preparedness and contributing to the UK’s growth mission.   #ModernaUK

🔬⚛️ On #WorldQuantumDay, we’re taking a closer look at how this evolving technology might change drug discovery. Wade Davis, SVP, Digital for Business at Moderna, weighs in on the potential—and the challenges ahead. Read more: https://lnkd.in/gtynsMA3